Address And Details

100 Vanguard Blvd. , Malvern, PA 19355
Fund Manager Binbin Guo
Manager Tenure 5 Years 5 Months

Strategy And Objective

The Fund seeks to provide long-term capital appreciation while limiting exposure to general stock market risk.The Fund follows a market neutral strategy, which the Fund defines as a strategy designed to produce a portfolio that is neutral with respect to general stock market risk (sometimes referred to as beta neutrality). Beta is a measure of a portfolio s volatility relative to the volatility of the general stock market. The Fund, as a whole, does not seek to adhere to any other definition of market neutrality.

Net Asset Value

as of 5:40 PM ET 09/24/2021

Performance

  • 1 Week
  • +1.31%
  • 1 Month
  • +0.30%
  • 3 Months
  • +3.83%
  • 1 Yr Return
  • +6.03%
  • 5 Yr Return
  • -14.07%

Equity Sector Breakdown

Technology 17.54%
Finance 17.35%
IndustrialCyclical 11.67%
RetailTrade 10.15%
NonDurables 9.18%
Services 8.90%
Health 4.70%
Utilities 3.65%
ConsumerDurables 2.19%
Energy 1.85%

Asset Allocation

Asset Type % Of Allocation
Stocks 96.39%
ForeignStocks 0.84%
Cash 0.00%
Bonds 0.00%
Preferred 0.00%
Convertible 0.00%
Other 0.00%
ForeignBonds 0.00%
ForeignHedged 0.00%
Total Net Assets 252.51 M

Risk Measures

Criteria 3 Years 5 Years 10 Years
Alpha -5.83 -3.45 -0.83
Beta 0.03 0.05 0.04
R Squared 0.01 0.01 0.01
Std Deviation 6.61 6.02 5.35
Sharpe Ratio -0.81 -0.45 n/a

Purchase Information

as of 5:45 PM ET 09/23/2021
Minimum Initial $50000
Minimum Additional $1
Minimum Initial IRA $0

Performance

Timeframe Average Annual Current Performance Monthly As Of 08/31/2021 Average Annual Current Performance Quarterly As Of 06/30/2021 Avg Annual Current Performance Monthly As Of 08/31/2021 Avg Annual Current Performance Quarterly As Of 06/30/2021
1 Year
  • +5.55%
  • +1.73%
+5.55% +1.73%
3 Year
  • -4.56%
  • -4.39%
-4.56% -4.39%
10 Year
  • +0.23%
  • +0.12%
+0.23% +0.12%
Life Of Fund
  • +1.76%
  • +1.67%
+1.76% +1.67%

Top 10 Holdings

Symbol Company Name % Of Assets
JEF JEFFERIES FINANCIAL GROUP IN 0.89%
SLM SLM CORP 0.86%
ALKS ALKERMES PLC 0.85%
BOX BOX INC 0.85%
JBL JABIL INC 0.85%
COMM COMMSCOPE HOLDING COMPANY IN 0.85%
HI HILLENBRAND 0.84%
DBX DROPBOX INC 0.84%
UGI UGI CORP 0.82%
GLPI GAMING & LEISURE PROPERTIE 0.82%

LATEST NEWS

Recent Articles from TheStreet

China Power Firms Suspend Publication Of Coal Data, Frustrating Analysis Of Industrial Production

Jim Cramer's Read on Industrial Production

Latest data remains encouraging for economy.

United Airlines

United Airlines Faces Department of Transportation Fine

United Airlines faces a $1.9 million fine from the Department of Transportation for violating federal statutes and a DOT rule prohibiting long tarmac delays.

NYSE Trader Lead

Jim Cramer IDs an Underappreciated Investing Rule

It's not enough to just identify stocks you want to own.

Home Construction, and Regional and Community Bank ETFs Reflect a Healthy Housing Market

Jim Cramer Says Latest Housing Data is Mixed for Millenials

There are signs more rental units are being built, but single family dwellings are still tight.

Closing Bell: Rite Aid Spikes on FTC Negotiations; U.S. Stocks Fall

Rite Aid Teams With Uber Eats for Nationwide On-Demand Delivery

Rite Aid expands its on-demand delivery options, adding a partnership with Uber Technologies to deliver products nationwide through Uber Eats.

Amazon Prime Lead

Whole Foods Adds Service Fee for Amazon Prime Deliveries

Amazon's Whole Foods Market is ending free deliveries for Amazon Prime members, as it will add a $9.95 service fee beginning in October.

FedEx Lead

FedEx Is a Sell, Guilfoyle Says

Delivery giant recently missed estimates and has been late to raise prices.

intel (4)

Intel Starts Construction of Two Arizona Computer Chip Factories

Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help meet the high demand for semiconductors in the U.S.

A technician works with genome samples at a biotech lab in Beijing. Photo: Reuters

Bret Jensen: Two Biotechs to Consider

Things are looking up for these drug companies as they make progress with the FDA